Financial Report: Actavis

Actavis

4Q Revenues: $4.1 billion (+46%)

4Q Loss: $732.9 million (loss of $148.4 million 4Q13)

FY Revenues: $13.1 billion (+51%)

FY Loss: $1.6 billion (loss of $750.4 million FY13)

Comments: North American Brands business revenues were $1.8 billion, up 188%, primarily driven by the acquisition of Forest, as well as double-digit growth for the Namenda franchise, Linzess, Estrace Cream, Teflaro, and Bystolic. North American Generics & International revenue was $1.8 billion, up 1%, with growth of generic versions of Lidoderm and Concerta, and 4Q launches of generic versions of Intuniv and Celebrex, offset by a decline of $80 million associated with the divested Western European assets in April 2014. Following the close of the merger with Allergan, the company will change its name to Allergan.